Kanabo Group Plc Stock price

Equities

KNB

GB00BYQCS703

Pharmaceuticals

Market Closed - London S.E. 12:35:09 2024-03-28 pm EDT 5-day change 1st Jan Change
1.75 GBX 0.00% Intraday chart for Kanabo Group Plc +7.69% -37.50%
Sales 2021 73K 92.15K Sales 2022 603K 761K Capitalization 8.04M 10.14M
Net income 2021 -4M -5.05M Net income 2022 -6M -7.57M EV / Sales 2021 648 x
Net cash position 2021 4.5M 5.68M Net cash position 2022 3.01M 3.8M EV / Sales 2022 8.33 x
P/E ratio 2021
-9.98 x
P/E ratio 2022
-1.15 x
Employees 23
Yield 2021 *
-
Yield 2022
-
Free-Float 61.92%
More Fundamentals * Assessed data
Dynamic Chart
1 week+7.69%
Current month-2.78%
1 month-2.78%
3 months-2.78%
6 months+2.94%
Current year-37.50%
More quotes
1 week
1.50
Extreme 1.5
2.00
1 month
1.50
Extreme 1.5
2.10
Current year
1.50
Extreme 1.5
3.20
1 year
1.15
Extreme 1.15
3.52
3 years
1.15
Extreme 1.15
29.00
5 years
1.15
Extreme 1.15
51.00
10 years
1.15
Extreme 1.15
51.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 46 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chairman 62 23-05-08
Director/Board Member 73 21-06-27
Director/Board Member 51 23-05-03
More insiders
Date Price Change Volume
24-03-28 1.75 0.00% 276,892
24-03-27 1.75 -2.78% 249,771
24-03-26 1.8 -2.70% 533,940
24-03-25 1.85 +13.85% 1,205,163
24-03-22 1.625 0.00% 409,990

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Kanabo Group plc is a United Kingdom-based patient-focused provider of digital health services and specialist medicines, including medicinal cannabis. The Company’s principal activities are the distribution and development of cannabis derived medical and wellness products. The Company is focused on the distribution of cannabis-derived products for medical patients, and non- tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. It has conducted research and development (R&D) in order to develop cannabis extract formulas, medical-grade vaporizers and various non-smoking consumption solutions. Its clinical and validation activities, including safety and efficiency tests, are conducted in Israel. The Company operates through two segments: Primary case and Secondary case. Primary case segment is involved in the telepharma services provided by GPS. Secondary case segment is involved in the distribution and development of cannabis-derived medical and wellness products.
More about the company
  1. Stock
  2. Equities
  3. Stock Kanabo Group Plc - London S.E.